Is West Pharmaceutical Services (WST) overvalued or fairly valued?

MarketChacha shows West Pharmaceutical Services's valuation in context — a trailing P/E of about 43.5, a forward P/E of about 34.3, a price-to-book of about 8.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does West Pharmaceutical Services's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.38×) from reported figures — education, not a rating.

What is West Pharmaceutical Services's revenue?

West Pharmaceutical Services reported revenue of $3.1B for FY2025, with net profit of $493.7M, per official filings.

What is the share price of West Pharmaceutical Services (WST)?

West Pharmaceutical Services last traded at $339.97 (-0.8% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

West Pharmaceutical Services

WST · NYSE · Healthcare · United States

Snapshot

TickerWST

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees10,800

HeadquartersExton, United States

Websitewww.westpharma.com

Filings tracked15

About West Pharmaceutical Services

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Who owns it

Insiders0.6%
Institutions99.4%
Public & other0.0%

1,207 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.45%
Vanguard Capital Management LLC6.56%
Vanguard Portfolio Management LLC5.71%
FMR, LLC5.08%
State Street Corporation4.76%
Artisan Partners Limited Partnership3.43%
Bank Of New York Mellon Corporation2.90%
Generation Investment Management LLP2.88%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 4.1 points over the period — profitability is trending down.

Cash conversion1.38×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend20.1% → 16.1%

Margin has compressed by about 4.1 points over the period — profitability is trending down.

Return on equity15.5%

Latest ROE of 15.5% — capital is generating a healthy return.

Growth qualityrev 2% · PAT -9%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $827.5M · EPS 2.27

Est. earnings growth +11.3%

Next fiscal year

Rev $3.6B · EPS 9.96

Est. earnings growth +11.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$3.1B

Net margin

16.1%

ROE

15.5%

Revenue CAGR (2y)

+2.1%

Profit CAGR (2y)

-8.8%

EPS (FY2025)

6.79

Net profit (FY2025)

$493.7M

Ask MarketChacha about WST

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$3.1B	$493.7M	6.79	16.1%	15.5%
FY2024	$2.9B	$492.7M	6.69	17.0%	18.4%
FY2023	$2.9B	$593.4M	7.88	20.1%	20.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$872.3M	$154.0M	2.15	17.7%
2026Q1	$844.9M	$138.8M	1.92	16.4%
2025Q3	$804.6M	$140.0M	1.92	17.4%
2025Q2	$766.5M	$131.8M	1.82	17.2%
2025Q1	$698.0M	$89.8M	1.23	12.9%
2024Q3	$746.9M	$136.0M	1.85	18.2%
2024Q2	$702.1M	$111.3M	1.51	15.9%
2024Q1	$695.4M	$115.3M	1.55	16.6%
2023Q3	$747.4M	$161.3M	2.14	21.6%
2023Q2	$753.8M	$155.1M	2.06	20.6%
2023Q1	$716.6M	$140.0M	1.85	19.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/23/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/23/2026material
8-K — Material agreement, Exhibits
SEC7/14/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/1/2026material
8-K/A — Exhibits
SEC5/20/2026
8-K — Reg FD disclosure, Exhibits
SEC5/11/2026material
8-K — Shareholder vote results, Exhibits
SEC5/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/23/2026material
10-Q filing
SEC4/23/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/9/2026material
10-K filing
SEC2/17/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/12/2026material

2025

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/23/2025material
10-Q filing
SEC10/23/2025
8-K — Executive/director change, Exhibits
SEC9/11/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.